JNJ241129C135000
- 0.00
- 0.000.00%
Johnson & Johnson Newsroom
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Investors in Johnson & Johnson (NYSE:JNJ) Have Seen Decent Returns of 30% Over the Past Five Years
Is Johnson & Johnson (JNJ) the Best Dividend Aristocrat Stock To Buy Right Now?
S&P 500, Dow Hit Records Right After Open | Live Stock
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
Johnson & Johnson To Go Ex-Dividend On November 26th, 2024 With 1.24 USD Dividend Per Share
Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch
Trump Nominates Marty Makary For FDA Commissioner
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program
Market Climbs, Bitcoin Close to $100k | Live Stock
Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis
Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and Others
Express News | Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya® (Guselkumab) in Ulcerative Colitis, a First for an Il-23 Inhibitor
Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days
Zevra Niemann-Pick Disease Type C Drug Miplyffa Now Available
Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are...